Study guide

High-Yield Oncology Safety and Emergency Tables

OCN Oncology Certified Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: OCN Exam Orientation and Official Source Control

Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness

2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care

Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures

3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment

Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation

4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards

Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development

5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy

Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation

6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents

Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation

7 Chapter 7: Symptom Management and Supportive Care

Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination

8 Chapter 8: Oncologic Emergencies and Rapid Escalation

Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

9 Chapter 9: Psychosocial Dimensions of Oncology Care

Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals

10 Chapter 10: Mixed OCN Case Labs

New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab

11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness

Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning

High-Yield Oncology Safety and Emergency Tables

Key Takeaways Explain This Topic AI

Oncologic emergencies (16% of the blueprint) test rapid recognition, first nursing actions, escalation, and patient education.

The safest OCN answer usually protects airway, circulation, neurologic function, vascular access integrity, or infection control before lower-urgency teaching.

High-yield emergencies include febrile neutropenia (ANC under 500, or under 1,000 and falling), tumor lysis syndrome, hypercalcemia, spinal cord compression, superior vena cava syndrome, and cardiac tamponade.

Modern OCN review must include immune-related adverse events and immune effector cell toxicities such as cytokine release syndrome (CRS) and ICANS.

Tables should be drilled as trigger-to-action prompts, not read passively.

Last updated: October 2026

  • High-Yield Oncology Safety and Emergency Tables
  • Use red flags, not memorized paragraphs

Final review for oncology safety should feel like triage practice. The OCN exam asks what the nurse should do first , which finding is most concerning , what teaching needs follow-up, or which patient needs immediate evaluation. The best answer usually protects airway, breathing, circulation, neurologic function, infection control, or tissue integrity.

Stay inside RN scope : assess, stop unsafe administration, maintain access, initiate ordered emergency protocols, notify the provider, activate rapid response, educate, and document. Answers that have the RN independently prescribe, or that delay care to "reassure" the patient, are usually distractors.

Emergency trigger table

Emergency Classic clues (with thresholds) Priority nursing response

Febrile neutropenia / sepsis Temp >=38.3C once or >=38.0C for 1 hour with ANC under 500 (or under 1,000 and falling); chills, hypotension, tachycardia Cultures then antibiotics within ~1 hour; rapid assessment; escalate

Tumor lysis syndrome (TLS) High K+, high phosphate, LOW calcium, high uric acid, rising creatinine after cytotoxic therapy Continuous telemetry, hydration, monitor labs, urgent provider notice

Hypercalcemia Corrected calcium above ~10.5 mg/dL; weakness, constipation, polyuria, confusion, short QT Assess hydration and mentation, fall precautions, isotonic fluids per orders

Spinal cord compression New or worsening back pain, leg weakness, sensory level, bowel/bladder change Neuro assessment, urgent escalation, dexamethasone/MRI per orders, limit mobility

Superior vena cava syndrome (SVCS) Face/neck/arm swelling, dyspnea, distended chest veins, headache Elevate head of bed, assess airway/breathing, urgent provider notice

Cardiac tamponade Dyspnea, hypotension, muffled heart sounds, jugular venous distention (Beck triad) Emergency assessment, oxygen/support, immediate escalation

Increased intracranial pressure Headache, vomiting, vision change, altered mentation, seizures Neuro assessment, protect airway, urgent escalation

Note the trap: in TLS calcium is low (it binds excess phosphate), even though hypercalcemia is itself a separate emergency.

Infusion and hazardous drug safety

Situation First move Avoid

Suspected anaphylaxis (wheeze, hypotension, tongue swelling) Stop infusion, keep IV access, assess ABCs, call for help, epinephrine per protocol Reassuring the patient without assessing

Mild infusion reaction Follow protocol, assess vitals/symptoms, notify as indicated Restarting without orders

Vesicant extravasation Stop infusion, leave catheter if policy requires, aspirate/antidote if directed, notify Flushing the line or pulling access before policy steps

Hazardous spill Use the spill kit and PPE per policy Cleaning with bare hands

Oral hazardous drug at home Teach safe storage, glove handling, separate disposal, missed-dose rule Crushing or splitting unless specifically instructed

Infusion items separate candidates who know a concept from those who choose the safe first action . Wheezing, hypotension, tongue swelling, chest tightness, or respiratory distress means stop the infusion and assess . Possible extravasation means do not flush . Hazardous exposure means protect staff, caregivers, and the environment first.

Immune-related emergencies

Checkpoint inhibitors (the -mab agents like pembrolizumab, nivolumab, ipilimumab) cause immune-related adverse events (irAEs) : pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, myocarditis, and severe skin reactions. CAR T-cell and bispecific antibody therapies cause cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) . Fever after immune effector therapy is never "routine" until assessed.

  • Toxicity Red flags OCN action logic
  • Pneumonitis New cough, dyspnea, hypoxia Escalate promptly; never label it expected fatigue

Colitis Persistent or bloody diarrhea, cramping, dehydration Notify the team; avoid casual antidiarrheal self-care advice

Endocrinopathy Profound fatigue, headache, hypotension, glucose/thyroid shift Assess and escalate; presentation can be subtle

Myocarditis Chest pain, dyspnea, arrhythmia, troponin rise Treat as life-threatening; urgent escalation

CRS Fever, hypotension, hypoxia after immune therapy Urgent assessment, protocol-based response (often tocilizumab)

ICANS Confusion, aphasia, tremor, deteriorating handwriting, seizure Neurologic emergency; escalate immediately

Practice method

Cover the action column and recite the first response; then cover the clue column and name the triggering symptoms. This active drill is faster than rereading and mirrors timed exam performance. Quick recall prompts: fever plus possible neutropenia is urgent; new back pain with weakness is cord compression until proven otherwise; new dyspnea during infusion is stop-and-assess; new confusion after immune effector therapy is ICANS until ruled out; abnormal labs matter most when paired with symptoms, a worsening trend, or high-risk therapy.

Why "first action" beats "correct diagnosis" on the OCN

Many candidates lose emergency items not because they cannot name the syndrome but because they pick a real, helpful action that is not the first one. The exam writes options where two or three choices are all reasonable later steps. The discipline is to ask: of these, which protects life or limb soonest and stays within RN scope?

Work a representative scenario. A patient three days after induction chemotherapy for acute leukemia spikes a temperature of 38.5C; the morning ANC was 300. Options might include: notify the provider, draw blood cultures, administer scheduled antiemetics, and document the temperature. The keyed first action is to recognize febrile neutropenia and move quickly toward cultures and the sepsis bundle — the standard is broad-spectrum antibiotics within roughly one hour of recognized neutropenic fever. Documentation and antiemetics are real tasks, but they do not address the time-critical infection risk.

A second pattern: a patient with lung cancer reports facial swelling and morning headache that worsens when bending forward, with distended neck veins. That is superior vena cava syndrome ; elevating the head of the bed and assessing the airway come before reassurance or routine teaching. Train your eye to separate the safe-now action from the merely-appropriate one, and the emergency domain becomes one of the most predictable on the test.